Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPA3 | P15088 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542313 | 0.97 | FOLH1 (0.56) | FOLH1TDP1SLC1A1CPA1CPB1 | |
| SCHEMBL28920282 | 0.94 | FOLH1 (0.54) | FOLH1TDP1SLC1A1CPA1CPB1 | |
| Tricarballylic Acid SCHEMBL11291769 | 0.85 | FOLH1 (0.62) | FOLH1TDP1CPA1CPB1CPA3 | |
| Tricarballylic Acid SCHEMBL28692658 | 0.82 | FOLH1 (0.59) | FOLH1TDP1CPA1CPB1CPA3 | |
| Tricarballylic Acid SCHEMBL1821947 | 0.82 | FOLH1 (0.65) | FOLH1TDP1CPA1CPB1CPA3 | |
| Ammonia Solution, Strong SCHEMBL16760976 | 0.82 | — | — | |
| Tricarballylic Acid SCHEMBL34866 | 0.82 | FOLH1 (0.65) | FOLH1TDP1CPA1CPB1CPA3 | |
| Tricarballylic Acid SCHEMBL2462503 | 0.79 | FOLH1 (0.62) | FOLH1TDP1CPA1CPB1CPA3 | |
| Tricarballylic Acid SCHEMBL11736211 | 0.79 | FOLH1 (0.62) | FOLH1TDP1CPA1CPB1CPA3 | |
| Tricarballylic Acid SCHEMBL11728494 | 0.79 | FOLH1 (0.62) | FOLH1TDP1CPA1CPB1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115047084-A | Use of blood lipids for milk product intake and disease prediction | 中国科学院上海营养与健康研究所 | 2022-09-13 | — | — | CN | disclosed |
| US-11427869-B2 | T cell balance gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114544924-A | Application of glyceride in disease prediction | 中国科学院上海营养与健康研究所 | 2022-05-27 | — | — | CN | disclosed |
| CN-114414668-A | Use of sphingolipids for disease prediction | 中国科学院上海营养与健康研究所 | 2022-04-29 | — | — | CN | disclosed |
| US-20210401953-A1 | ASPARAGINASE THERAPEUTIC METHODS | THE BROAD INSTITUTE, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20200317767-A1 | GROWTH DIFFERENTIATION FACTOR (GDF) FOR TREATMENT OF DIASTOLIC HEART FAILURE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2020102427-A1 | ASPARAGINASE THERAPEUTIC METHODS | THE BROAD INSTITUTE, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-2828289-B1 | GROWTH DIFFERENTIATION FACTOR (GDF) 11 FOR TREATMENT OF AGE-RELATED CARDIOVASCULAR CONDITION | BRIGHAM & WOMENS HOSPITAL INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10446259-B2 | Systems, apparatus, and methods for analyzing and predicting cellular pathways | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180340022-A1 | GROWTH DIFFERENTIATION FACTOR (GDF) FOR TREATMENT OF DIASTOLIC HEART FAILURE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-11-29 | — | — | US | disclosed |
| US-6706893-B2 | BY HYDROGENATION OF STARTING MATERIALS INCLUDING SUCCINIC ACID, N-METHYLSUCCINIMIDE; EFFICIENCY | BATTELLE MEMORIAL INSTITUTE | 2004-03-16 | — | — | US | disclosed |
| US-6670483-B2 | Catalytically hydrogenating n-methyl-succinimide to form n-methylpyrrolidone | BATTELLE MEMORIAL INSTITUTE | 2003-12-30 | — | — | US | disclosed |
| US-6632951-B2 | Making N- methylpyrrolidine and analogous compounds via hydrogenation. Novel catalysts for this process, and novel conditions/yields are also described. Other process improvements may include extraction and hydrolysis steps. | BATTELLE MEMORIAL INSTITUTE | 2003-10-14 | — | — | US | disclosed |
| US-6603021-B2 | Making pyrrolidones, especially N-methyl pyrrolidone (\"NMP\"), by hydrogenation of succinimides | BATTELLE MEMORIAL INSTITUTE | 2003-08-05 | — | — | US | disclosed |
| US-20030125570-A1 | Methods of making pyrrolidones | WERPY TODD (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030120087-A1 | Methods of making pyrrolidones | WERPY TODD (US) | 2003-06-26 | — | — | US | disclosed |
| US-20030114687-A1 | Methods of making pyrrolidones | WERPY TODD (US) | 2003-06-19 | — | — | US | disclosed |
| US-20030097006-A1 | Methods of making pyrrolidones | ENERGY, U.S. DEPARTMENT OF | 2003-05-22 | — | — | US | disclosed |
| EP-0232736-A1 | Preparation of 4'-aminomethylfluorescein derivatives for use in fluorescence polarization immunoassays | ABBOTT LABORATORIES (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0201751-A2 | 4'-aminomethyfluorescein derivatives for use in fluorescence polarization immunoassys | ABBOTT LABORATORIES (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120087-A1 | Methods of making pyrrolidones | HPD, HNMT, DHPS | FOLH1 743/4885TDP1 1179/4885SLC1A1 2126/4885 |
| US-20030125570-A1 | Methods of making pyrrolidones | HPD, HNMT, DHPS | FOLH1 743/4885TDP1 1179/4885SLC1A1 2126/4885 |
| US-20030114687-A1 | Methods of making pyrrolidones | HPD, HNMT, DHPS | FOLH1 743/4885TDP1 1179/4885SLC1A1 2126/4885 |
| US-20030097006-A1 | Methods of making pyrrolidones | HPD, HNMT, DHPS | FOLH1 743/4885TDP1 1179/4885SLC1A1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.